Stability study of an injectable hospital preparation of naloxone hydrochloride as part of a clinical trial

9 October 2015

ML. Tall1, EH. Diouf1, D. Laleye1, C. Dhelens1, M. Lenfant1, B. Ducarre1, N. Koog1,D. Salmon1,2, F. Pirot1,2, C. Pivot1 1 Pharmacie, Groupement Hospitalier Edouard Herriot, 5 place d’Arsonval, 69437 Lyon cedex 03, France
2 Laboratoire de Recherche et développement de Pharmacie Galénique Industrielle, Faculté de Pharmacie, Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69373 Lyon cedex 08, France


The injectable hospital preparation of naloxone hydrochloride dosed at 0.4 mg/ml is administered by parenteral route as part of a multicentric double-blind clinical trial. This clinical research focuses on the evaluation of efficacity of the administration of naloxone 0.4 mg or placebo (Sodium chloride 0.9%) in the reduction of severe dysfunction of post-critical tonic-clonic seizures. To meet regulatory requirements and have ready to use preparation with an expiration date, a stability study was realised.

This hospital preparation was realised in an isolator under aseptic conditions associated with sterilizing filtration. Bottles of glass vials type II (5 ml filled to 1 ml with of solution) prepared were stored in a climatic chamber at 25°C ± 2°C. To assess the stability of the finished product, the physicochemical controls (dosage of naloxone by liquid chromatography, sodium concentration, measurement of pH, osmolality, particle sub-visible particles) and microbiologicals (bacterial endotoxin and sterility) were realised during one year from a pilot batch.

Results and discussion

Throughout the stability study, neither significant decrease of naloxone concentration and sodium concentration nor pH and osmolality variation were observed. The variation of the concentration of naloxone remaining relative to the initial concentration was between 98.9% and 103.6%. The sub-visible particles, the bacterial endotoxin and sterility were in accordance with the European Pharmacopoeia attesting limpidity, apyrogenicity and sterility of this injectable preparation.


The hospital preparation was stable over one year at 25°C ± 2°C ensuring to safe a parenteral administration for human as part of the clinical trial.

Key words : Naloxone hydrochloride, Hospital preparation, Stability study, Clinical trial, Tonic-clonic seizures.

Discussion forum

GERPAC provides for its members a discussion forum specifically devoted to technology in hospital pharmacy

Access forum

Association Loi 1901
Siège social : Chez Jean-Yves Jomier / 8ter rue Léon Bussat, 64000 PAU
Immatriculation formation N° 72 64 035 30 64
Contact us Legal notes - Management of personal data
Réalisation : Développeur web WordPress & SPIP freelance